Sean Saint

Yeah.

Right now, the standard of care, if you will, or the standard with the agency is that you do need a clinical trial.

Whether or not that will remain that way or will always be that way, we don't know.

But right now, that is the expectation.

Yes, we have plans to do this, to seek the indication.

I do want to set expectations, though, in my view.

I don't think it really will accelerate when we get the, if we were to have, maybe I should say it that way, the type two indication.

I just, you know, I've talked to a heck of a lot of healthcare providers and they do understand the tools that they use and where they can be well utilized.

So my expectation is not that it would expand massively, but I can always be proved wrong.

Regardless, it's the right thing to do to pursue that.

So we'll do it for that reason.

Yeah.

So first of all, let me say that islet today is really two things.

It's the physical pump itself, which is a durable component, and it's the algorithm that goes on that pump.

So in our mint program, which is our our patch pump program and development, we're switching out the hardware while maintaining the algorithm.

So all the user experience stuff that we've talked about in terms of no carb counting and no setup or weight based setup and learning and adaptation, all those things stay with our mint program with a form factor that you can wear on your body.

We have chosen a two-part reusable architecture.

One's disposable, one's reusable.

And there's a lot of good reasons for that.

We believe that's the right way to go.